DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Military.com - 1 Beth Teach - 1 Cpl - 1 Juan Torres - 1 Capt - 1 Pedro Caballero - 1 Caballero - 1
Top related locs:
Japan Port Australia Miramar , California Darwin Washington , Lemonnier Djibouti
Top related orgs:
Moderna - 3 UBS - 2 Service - 1 Force - 1 Marine Corps - 1 Ospreys - 1 Business - 1 Navy - 1

Search resuls for: "CMV"


6 mentions found


☆ V-22 Ospreys return to the skies but are required to stay within 30 minutes from an airfield in case of emergency
  + stars: | 2024-05-20 | by ( Thomas Novelly | Drew F. Lawrence | Konstantin Toropin | ) www.businessinsider.com   time to read: +8 min
The Joint Program Office declined to comment to Military.com regarding the restriction. A spokesperson for the Marine Corps could not provide details on the restriction but said efforts are underway to return the aircraft to full operations. Pedro Caballero, a spokesperson for the Marine Corps, told Military.com when asked whether the restrictions applied to its roughly 350 Ospreys, the vast majority of the military's fleet. US Marine Corps MV-22B Ospreys take off at Port Darwin in Australia. An MV-22B Osprey conducts an external lift with US Marines during helicopter support team training at Marine Corps Air Station in Miramar, California.
Persons: —, Military.com, Beth Teach, Cpl, Juan Torres, Capt, Pedro Caballero, Caballero, Colton Martin Lt, Rebecca Heyse, Amelia Kang, Brian Taylor, Taylor, Juan Paz Taylor Organizations: Service, Force, Marine Corps, Ospreys, Business, Navy, Naval Air Forces, Office, Naval Air Systems Command, Royal Australian Air Force Base, US Marine Corps, Corps, Port Darwin, Air Force Special Operations Command, Greyhound, House Armed Services, US Marines, Marine Corps Air, Services, Aviation, Air Force, Marines, Program Office, Marine, US Air National Guard, Staff Locations: Japan, Port, Australia, Miramar , California, Darwin, Washington ,, Lemonnier, Djibouti
☆ Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
  + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Moderna has more to offer beyond its Covid vaccine. The update brings Moderna a step closer to having multiple products on the market, which it badly needs amid plunging demand for Covid shots worldwide. Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston focused on the company's vaccine portfolio. That includes its combination vaccine against Covid and the flu and a shot against another common herpes virus called cytomegalovirus, or CMV. It also includes a new and improved version of Moderna's Covid shot.
Persons: norovirus, Barr, Moderna, Blackstone, Stéphane Bancel Organizations: Moderna, Epstein, Covid, Blackstone Life Sciences, Blackstone Group Locations: Boston, U.S
☆ UBS upgrades Moderna, says potential from new vaccines is underappreciated
  + stars: | 2023-06-26 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Investors aren't fully appreciating the broader uses for Moderna's mRNA vaccines, creating a big buying opportunity, UBS said Monday. UBS did lower its price target to $191 from $221, though the new forecast implies upside of 61% from Friday's close. MRNA YTD mountain Moderna stock has declined nearly 35% so far this year. Merle pointed toward vaccines for respiratory syncytial virus (RSV), the flu and cytomegalovirus (CMV) as promising upside drivers for the company. "We think MRNA's CMV vaccine could be a major potential upside driver over the next 1-2 years, with limited priced in (leading cause of birth defects, no approved vaccines)," Merle said.
Persons: Eliana Merle, Merle, Michael Bloom Organizations: UBS, Moderna, UBs Locations: Moderna, Friday's, CMV
☆ Here are Monday's biggest analyst calls: Meta, Tesla, Disney, Amazon, Boeing, Walmart, Uber & more
  + stars: | 2023-06-26 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
Here are Monday's biggest calls on Wall Street: Bank of America upgrades Alliant to buy from neutral Bank of America said shares of the Wisconsin and Iowa energy company are attractive. UBS upgrades Moderna to buy from neutral UBS said the biotech company's pipeline is underappreciated. UBS downgrades Alphabet to neutral from buy UBS said it sees "near-term monetization risk" for the tech giant. Bank of America reiterates Paramount Global as buy Bank of America said the media company is "unique." Loop reiterates Disney as buy Loop said it's standing by its buy rating on the entertainment and parks giant.
Persons: LNT, Goldman Sachs downgrades Tesla, Goldman, Morgan Stanley, TD Cowen, Coinbase, underperform TD Cowen, Wells, Brinker, Williams, Tesla, Bernstein, Uber, Davidson, Roth, Roth MKM, Piper Sandler, Lululemon, Piper, LULU Organizations: Bank of America, of America, UBS, Moderna, Walmart, Amazon Prime, BTC, BMO, Sherwin, Deutsche Bank, Deutsche, Citi, Boeing, WSFS Financial Corporation, Networks, TAM, Meta, Paramount Global, Brunswick Locations: Wisconsin, Iowa, China
☆ After 35 years in flight, the US military says it's done buying one of its most unique and controversial aircraft
  + stars: | 2023-05-05 | by ( Stavros Atlamazoglou | ) www.businessinsider.com   time to read: +8 min
Since its first flight in 1989, the V-22 Osprey has provided a unique capability to the US military. One of them is the V-22 Osprey, a unique and controversial aircraft that has carried conventional troops and special operators around the world for two decades. US Navy/Vernon PughIn the three decades since its first flight, the V-22 Osprey has brought a distinct capability to the US military's aviation fleet, despite its troubled development. Conventional and special-ops missionsUS Air Force special tactics operators fast rope from a CV-22B during an exercise in the UK in April 2021. In August 2022, Air Force Special Operations Command grounded its CV-22s over issues with its clutch, which had caused several "safety incidents."
☆ Moderna exec says COVID trials improved diversity recruiting
  + stars: | 2022-11-30 | by ( Caroline Humer | ) www.reuters.com   time to read: +1 min
[1/4] Chief Medical Officer of Moderna Paul Burton attends the Reuters NEXT Newsmaker event in New York City, U.S., November 30, 2022. REUTERS/Brendan McDermidNEW YORK, Nov 30 (Reuters) - Moderna Inc's top scientist said on Tuesday that the vaccine maker has learned how to better recruit from diverse populations for its clinical trials from running its COVID-19 vaccine studies. Moderna has worked to match that diverse enrollment in its other ongoing trials, Burton said. He said enrollment of people of color in its Respiratory Syncytial Virus (RSV) and Cytomegalovirus (CMV) vaccine trials was probably over 35%. To view the Reuters NEXT conference live on Nov. 30 and Dec. 1, please click here.
0 next >>
Total: 6